Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California. Drugs. Spectrum develops and markets drugs for treatments in oncology. In development. As of 2019, a number of drugs are investigated in clinical trials. Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010. Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.